Optimizing First-Line and Sequential Therapy in Advanced NSCLC
Panelists discuss how biomarkers like PD-L1 guide first-line therapy in advanced non-small cell lung cancer (NSCLC), with higher expression favoring PD-1 inhibitors. Other factors like performance status and comorbidities also support their use. Post progression, PD-1 inhibitors are often used alone or in combination for subsequent lines of treatment.
Video content above is prompted by the following:
- What role do biomarkers like PD-L1 play in determining first-line therapy options for advanced NSCLC, and how does level of expression impact initial drug choice?
- What other patient characteristics influence initial treatment choices in advanced NSCLC, and how do they support using PD-1s as first-line options?
- Following disease progression on initial therapy, how frequently are PD-1 inhibitors used alone or in combination for subsequent lines of treatment?
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Lurbinectedin and Atezolizumab Combo Improves Survival in Extensive-Stage Small-Cell Lung Cancer
June 20th 2025When small-cell lung cancer (SCLC) has spread to distant parts of the body, it’s classified as extensive-stage, which applies to nearly two-thirds of SCLC cases at the time of diagnosis.
Read More
